CorMedix
CRMD
73 hedge funds and large institutions have $31.3M invested in CorMedix in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 28 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 74 → 73 (-1)
5.04% less ownership
Funds ownership: 31.77% → 26.73% (-5%)
37% less capital invested
Capital invested by funds: $49.4M → $31.3M (-$18.1M)
45% less call options, than puts
Call options by funds: $308K | Put options by funds: $559K
54% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$589K |
| 2 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$307K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$260K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$190K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$163K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$2.52M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$903K |
| 3 |
Morgan Stanley
New York
|
-$591K |
| 4 |
Millennium Management
New York
|
-$487K |
| 5 |
WCP
Wick Capital Partners
Wayne,
Pennsylvania
|
-$461K |
CRMD Hedge Fund Activity: Q3 2022 in Review
73 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2022, worth a combined $31.3M — down 37% from $49.4M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CRMD and 12 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 13 added.
The largest buyer was Vanguard Group, adding an estimated $589K. The largest seller was Barclays, cutting an estimated $2.52M.
- 73 institutional investors held CorMedix (CRMD) as of Q3 2022, down from 74 in Q2 2022.
- Funds reported $31.3M of CorMedix stock for Q3 2022, down 37% quarter-over-quarter.
- 12 funds opened new CorMedix positions in Q3 2022 and 13 closed out, a net change of -1 holder.
- The largest CorMedix buyer in Q3 2022 was Vanguard Group, an estimated $589K added.
- The largest CorMedix seller in Q3 2022 was Barclays, an estimated $2.52M sold.
Based on aggregated 13F filings for Q3 2022.